As of 11:12am ET
| -0.0099 / -2.30%|
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular has concluded a phase 2 trial of its lead product candidate, ICT-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing T-cells. The company was founded by John S. Yu on March 20, 1987 and is headquartered in Calabasas, CA.
|John S. Yu||Chairman, Secretary & Chief Scientific Officer|
|Andrew Gengos||President, Chief Executive Officer & Director|
|Steven J. Swanson||Senior Vice President-Research|
|Anthony J. Gringeri||Senior Vice President-Strategic Resources|
|David E. Fractor||Chief Accounting Officer & Vice President-Finance|